| Posts by NTTG |
| Message | Subject | Recs | Posted |
not complaining at all, read it again (you will hear chuckling now)  | Provectus Pharmaceuticals Inc. | 1 | yesterday |
| Only when they can not get ink on paper | Provectus Pharmaceuticals Inc. | 2 | Sunday |
| Funding the PIII will not be a problem for PVCT, the shelf is full of shares yet | Provectus Pharmaceuticals Inc. | 2 | last Saturday |
| Not at all, the company is on record stating they wanted more aggressive dosing. | Provectus Pharmaceuticals Inc. | 1 | last Friday |
| Based on the dosing information you recently 'discovered' I dont see muc | Provectus Pharmaceuticals Inc. | 1 | last Friday |
| Your source on that news is? | Provectus Pharmaceuticals Inc. | 1 | last Friday |
| Neither option is a likely outcome here. Look at the molecules that have gotte | Provectus Pharmaceuticals Inc. | 1 | last Friday |
| Most of the delays are the result of poor planning at PVCT and over interpretati | Provectus Pharmaceuticals Inc. | 1 | last Thursday |
| He does seem to think so, doesn't he | Provectus Pharmaceuticals Inc. | 1 | last Thursday |
| That is just Vonny and I chatting, nothing for you to worry about | Provectus Pharmaceuticals Inc. | 1 | last Thursday |
| The company was slow to 'lock data' after completion of the PII trial; t | Provectus Pharmaceuticals Inc. | 1 | last Wednesday |
| LOL...they are hardly the audience of interest | Provectus Pharmaceuticals Inc. | 1 | last Wednesday |
| Because of the imaging needed to document a secondary 'bystander' end-po | Provectus Pharmaceuticals Inc. | 1 | last Wednesday |
| cost of the drug is budget dust for PIII trials, and approval has nothing to do | Provectus Pharmaceuticals Inc. | 1 | last Wednesday |
| They do already | Provectus Pharmaceuticals Inc. | 2 | last Wednesday |
| I understand how this board operates, really not that hard to figure out. | Provectus Pharmaceuticals Inc. | 1 | last Wednesday |
| That has been tried before. Turns out there are readers who appreciate the alter | Provectus Pharmaceuticals Inc. | 1 | June 11 |
| who would the competition be? | Provectus Pharmaceuticals Inc. | 1 | June 11 |
| The others have well thought out and executed R&D programs, their statements | Provectus Pharmaceuticals Inc. | 1 | June 11 |
| It is highly unlikely that nodal stage III or stage IV patients will be included | Provectus Pharmaceuticals Inc. | 1 | June 11 |
| Because I can make money buying and selling shares (not as much as I use too, or | Provectus Pharmaceuticals Inc. | 1 | June 11 |
| WOW....Lenvatinib doubles progression free survival in chemo naive stage IV mela | Provectus Pharmaceuticals Inc. | 1 | June 10 |
| They could not pay for the NDA | Provectus Pharmaceuticals Inc. | 1 | June 10 |
| Much better than yours | Provectus Pharmaceuticals Inc. | 1 | June 10 |
| What would I learn here that I do not know already about PVCT? I understood exa | Provectus Pharmaceuticals Inc. | 2 | June 10 |
| because the FDA negotiations are not finalized yet, so what are they going to te | Provectus Pharmaceuticals Inc. | 1 | June 10 |
| The question was about FDA allowable dosing for the PIII MM trial. The company i | Provectus Pharmaceuticals Inc. | 1 | June 10 |
| :-) sure, take your time | Provectus Pharmaceuticals Inc. | 1 | June 10 |
| you can read my posts over the years, benchmark them against company performance | Provectus Pharmaceuticals Inc. | 2 | June 9 |
| Just asking him to substantiate the claim...simple stuff | Provectus Pharmaceuticals Inc. | 2 | June 8 |
| Who are you? | Provectus Pharmaceuticals Inc. | 1 | June 8 |
| I asked you to publicly present the evidence, simple stuff | Provectus Pharmaceuticals Inc. | 2 | June 7 |
| How are you doing finding that dose information? I have not worked for ORNL or | Provectus Pharmaceuticals Inc. | 1 | June 7 |
| Pfizer entered into a global strategic agreement with CytomX for future commerci | Provectus Pharmaceuticals Inc. | 1 | June 7 |
| Not at ant time, not in any capacity. Jack stated that I have, ask him/her for | Provectus Pharmaceuticals Inc. | 1 | June 7 |
| They are the metrics that identify biotech companies making serious progress in | Provectus Pharmaceuticals Inc. | 1 | June 7 |
| You were originally suppose to see the PIII trial start in 2011 if you go back | Provectus Pharmaceuticals Inc. | 3 | June 7 |
| just read the posts all around the board these days | Provectus Pharmaceuticals Inc. | 1 | June 6 |
| Too funny Jack, when was I ever employed by PVCT? | Provectus Pharmaceuticals Inc. | 1 | June 6 |
| A growing number of longs have also become obviously and vocally frustrated by P | Provectus Pharmaceuticals Inc. | 1 | June 6 |
| The only constants for PVCT are that the SP continues to decline, deadlines are | Provectus Pharmaceuticals Inc. | 1 | June 6 |
| Jack, it is a simple question; If the data is so great and the story is so stron | Provectus Pharmaceuticals Inc. | 3 | June 6 |
| But you were not trying to save lives when you were an out of work teenager, wer | Provectus Pharmaceuticals Inc. | 2 | June 6 |
| Then why the delay getting a PIII started if the news is so good? | Provectus Pharmaceuticals Inc. | 3 | June 6 |
| The only point PVCT investors need to think about is: "The criteria for bre | Provectus Pharmaceuticals Inc. | 3 | June 6 |
| Information here is all old news, and some poor cut and paste attempts to create | Provectus Pharmaceuticals Inc. | 1 | June 5 |
| Nope. | Provectus Pharmaceuticals Inc. | | June 3 |
| Market for PV-10 is getting smaller and smaller. Huge movement in oncology to l | Provectus Pharmaceuticals Inc. | 2 | May 30 |
| dont forget to ask about per cycle and cumulative dose limits, and the frequency | Provectus Pharmaceuticals Inc. | 1 | May 23 |
| What per cycle and cumulative PV-10 dose will they use in PIII trial? All visibl | Provectus Pharmaceuticals Inc. | 1 | May 23 |
Copyright © 1995-2013 Knight Sac Media. All rights reserved.
